TGFB1 and idiopathic pulmonary fibrosis: Pirfenidone, an approved IPF antifibrotic, indirectly inhibits TGF−β1–mediated epithelial-mesenchymal transitions by suppressing MUC1−CT phosphorylation and β−catenin signaling, reducing α−SMA and collagen expression in preclinical models (166).